Additional SAVR trial patients will have no impact until the results of the study are released early next year. TAVR trials - maybe but not particularly likely and even so it wont impact our bankruptcy risk issue.
To have any hope of retaining our IP we need cash in the next couple of months. I favour a CR over a fire sale (though major shareholders and placement companies will probably dilute us to hell anyway). Best case would be a US listing in my view (if possible).
Additional SAVR trial patients will have no impact until the...
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |